ARCHIVES

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

This article is from The Cancer Letter archive.

Vol. 33 No. 2 | February 26, 2010

Download PDF Visit The Full Archive

Related Articles

No Benefit For Cetuximab In Early-Stage Colon Cancer

December 25, 2009

Limit On Number Of Surgery Planning Grants Lifted After DCT Board Pressure

March 19, 1982

In Brief: Big Ten Cancer Research Consortium Names Executive Officer

May 30, 2014

Fischinger Names HHS AIDs Coordinator; DeVita Appoints Maryann Roper Acting Deputy Director

October 30, 1987

Also in this 8-page issue: NIH opens 240-bed Hatfield Clinical Research Center.

September 24, 2004

FDA Approves Afinitor-Aromasin Regimen For Advanced HER2-Negative Breast Cancer

July 27, 2012